The initial Pompe treatment made two adult patients weaker, prompting Amicus to stop the trial and request an FDA clinical hold.
The initial Pompe treatment made two adult patients weaker, prompting Amicus to stop the trial and request an FDA clinical hold.
![John Crowley - Biotech's Chief Evangelist - [Art of Investing, EP.15]](https://megaphone.imgix.net/podcasts/c90bd084-e311-11ee-be41-d73b90879448/image/50d7c1b22c46d0e8199c451593610ee5.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress)
More from this episode
See all →A German infant failing approved Pompe therapy improved on Amicus’s experimental treatment,…
The failed Pompe drug weakened patients because its half-life in human muscle differed from its…
The Pompe enzyme treatment normalized the children’s enlarged hearts within six infusions or 12…
In the 1990s, science and biopharma transformed HIV/AIDS from a death sentence into a manageable…
A doctor predicted a Pompe disease cure within about a year. Nearly 25 years later, that goal…
About 90% of drugs entering clinical trials never become commercial products, while about 90% of…
An angel round raised $1 million from 37 individual investors after the minimum investment fell…
Amicus’s global pivotal Pompe study enrolled about 120 people and cost more than half a billion…
Don't lose this one
A free account saves cards like this to your Collection, and Korva resurfaces them so you actually remember.